

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lloyd S. Gray, et al. **Examiner:** Sheela Jitendra Huff
Serial No.: 10/589,216 **Art Unit:** 1643
Filed: January 15, 2008 **Docket:** 18467
For: INHIBITING CAV3 ISOFORMS **Dated:** July 21, 2008
AND THE 825B SPLICE VARIANT FOR THE
DIAGNOSIS AND TREATMENT OF CANCER

Confirmation No.: 5782

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. United States Patent No. 6,413,967 B1, dated July 2, 2002 to Gray et al.;
2. PCT International Publication No. WO 01/62740 A1, published August 30, 2001;
3. Nebe B. et al., "Induction of Apoptosis by the Calcium Antagonist Mibepradil Correlates with Depolarization of the Membrane Potential and Decreased Integrin Expression in Human Lens Epithelial Cells", *Graefe's Archive for Clinical and Experimental Ophthalmology* 242(7):597-604 (2004), XP-002483831;

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: July 21, 2008



Peter I. Bernstein

4. Cao Z. et al., "Angiotensin Converting Enzyme Inhibition and Calcium Antagonism Attenuate Streptozotocin-Diabetes-Associated Mesenteric Vascular Hypertrophy Independently of Their Hypotensive Action", *Journal of Hypertension* 16(6):793-799 (1998), XP-000866135;
5. Heady T.N. et al., "Molecular Pharmacology of T-Type Ca²⁺ Channels", *Japanese Journal of Pharmacology* 85(4):339-350 (2001), XP-002483849; and
6. Lee J-H et al., "Nickel Block of Three Cloned T-Type Calcium Channels: Low Concentrations Selectively Block α_{1H}", *Biophysical Journal* 77(6):3034-3042 (1999), XP-002483848.


The references were cited in a Supplementary Partial Search Report dated June 24, 2008 received from the European Patent Office. Applicants are submitting a copy of the above-cited references required by 37 C.F.R. §1.98 (a)(2)(i) and (ii) together with a copy of the Supplementary Partial Search Report. The relevance of the above-identified references has been described in the Supplementary Partial Search Report. It is further respectfully submitted that the other nine references cited in the Supplementary Partial Search Report, namely, Bertolesi, G.E. et al., "The Ca²⁺ Channel Antagonists Mibepradil and Pimozide Inhibit Cell Growth via Different Cytotoxic Mechanisms", *Molecular Pharmacology*, 62(2):210-219 (2002); PCT International Publication No. WO 99/29847, published June 17, 1999; Haverstick, D.M. et al., "Inhibition of Human Prostate Cancer Proliferation *in Vitro* and in a Mouse Model by a Compound Synthesized to Block Ca²⁺ Entry", *Cancer Research* 60(4):102-1008 (2001); Mariot, P. et al., "Overexpression of an α_{1H} (Ca_v3.2) T-type Calcium Channel during Neuroendocrine Differentiation of Human Prostate Cancer Cells", *The Journal of Biological Chemistry* 277(13):10824-10833 (2002); Jung-Bum S., "Identification of genes involved in sensory neuron mechanotransduction", *Dissertation Zur Erlangung Des Akademischen Grades Doktorum Rerum Naturalis* [Online] 28 February 2003, pp 1-109, retrieved from the Internet:
[URL: http://www.diss.fu-berlin.de/2003/68/05_methods.pdf](http://www.diss.fu-berlin.de/2003/68/05_methods.pdf); Yunker, A.M.R. et al., "Immunological

Characterization of T-Type Voltage-Dependent Calcium Channel CA_v3.1 (Alpha1G) and CA_v3.3 (Alpha1I) Isoforms Reveal Differences in Their Localization, Expression, and Neural Development”, *Neuroscience* 117(2):321-335 (2003); PCT International Publication No. WO2005/079316 A2, published September 1, 2005; Niwa, N. et al., “Immunoblotting of T-Type Ca²⁺ Channel Protein in Mouse Brain and Embryonic Heart by Using Two Antibodies against Ca_v3.1 Channels”, *Environmental Medicine* 47:42-44 (2003); and PCT International Publication No. WO 2004/000311 A2, published December 31, 2003 were previously cited in Applicants’ Information Disclosure Statement filed on January 15, 2008, and therefore copies of these nine references are not provided.

Further, the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Inasmuch as this Information Disclosure Statement is also being submitted in accordance with the schedule set out in 37 C.F.R. §1.704(d), a statement is attached.

Respectfully submitted,



Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg